NDAOPHTHALMICSOLUTION/DROPS
Approved
Nov 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
ACULAR (ketorolac tromethamine) by AbbVie is anti-inflammatory drug which, when administered systemically, has demonstrated analgesic, anti-inflammatory, and anti-pyretic activity. First approved in 1992.
Drug data last refreshed 11h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Acular (ketorolac tromethamine) is a nonsteroidal anti-inflammatory drug (NSAID) formulated as an ophthalmic solution for topical eye use. It reduces inflammation and pain in the eye by inhibiting prostaglandin biosynthesis. The drug is indicated for post-operative ocular inflammation and pain management following cataract surgery and other ophthalmic procedures.
$0.075BPart D
LOE ApproachingLong-established product approaching loss of exclusivity with modest Part D utilization; commercial team likely focused on maintenance and managed care positioning rather than growth initiatives.
Mechanism of Action
anti-inflammatory drug which, when administered systemically, has demonstrated analgesic, anti-inflammatory, and anti-pyretic activity. The mechanism of its action is thought to be due to its ability to inhibit prostaglandin biosynthesis.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Study of CU06-1004 in Patients With Daibetic Macular Edema
Started Dec 2026
156 enrolled
DMEDiabetic Macular EdemaDiabetic Macular Edema (DME)
Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration
Started Jun 2026
15 enrolled
Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
A Study to Assess the Use of Artificial Intellignce to Predict Eye Treatment Changes in Adult Participants With Diabetic Macular Edema
Started May 2026
554 enrolled
Diabetic Macular Edema
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
Started May 2026
304 enrolled
Neovascular Age-related Macular DegenerationnAMD
Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema
Started May 2026
576 enrolled
Diabetic Retinopathy
Worked on ACULAR at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.